|
|
| C O N T E N T S | |
|
|
|
Home |
|
|
|
To our readers |
|
|
|
Features |
|
|
|
Benefactors |
|
|
|
Featured Clinical Trial |
|
|
|
Calendar of Events |
|
|
|
News |
|
|
|
Contact |
|
|
|
Subscribe |
|
|
|
Past issues |
 |
||||||||||||||||||
 |
||||||||||||||||||
 |
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
|
|
|
 |
||
 |
||
|
Using nanotechnology, bits of sugars, amino acids and polymers can be combined
into new molecules known as synthetic high-affinity ligands (SHALs). Researchers at Lawrence Livermore National
Laboratory and UC Davis Cancer Center are collabo-rating to create SHALs that will target cancer cells. |
||
 |
||
| Synthesis is also available as a PDF for easy viewing and printing. |
|
|
|
UC DAVIS CANCER CENTER cancer.center@ucdmc.ucdavis.edu © 2005 UC Regents. All rights reserved. |